NASDAQ:SRPT Sarepta Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $75.22 +3.40 (+4.73%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$70.33▼$75.4650-Day Range$62.69▼$81.6752-Week Range$61.28▼$101.24Volume1.74 million shsAverage Volume584,055 shsMarket Capitalization$6.58 billionP/E RatioN/ADividend YieldN/APrice Target$119.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRPT Stock Forecast (MarketRank)Overall MarketRank™2.14 out of 5 starsMedical Sector443rd out of 1,417 stocksPharmaceutical Preparations Industry186th out of 675 stocksAnalyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.25, Sarepta Therapeutics has a forecasted upside of 58.5% from its current price of $75.22.Amount of Analyst CoverageSarepta Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesSarepta Therapeutics has received 1,372 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSarepta Therapeutics has received 417 “underperform” votes. (Add your “underperform” vote.)Community SentimentSarepta Therapeutics has received 76.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote “Outperform” if you believe SRPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions81.43% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow in the coming year, from ($4.54) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -17.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -17.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sarepta Therapeutics (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock News HeadlinesJune 26, 2022 | americanbankingnews.comCantor Fitzgerald Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $128.00June 26, 2022 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) PT Lowered to $90.00 at Credit Suisse GroupJune 24, 2022 | seekingalpha.comSarepta gains as analysts say clinical hold on Duchenne candidate not a major setbackJune 24, 2022 | finance.yahoo.comSarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051June 24, 2022 | americanbankingnews.comAnalysts Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $121.08June 23, 2022 | investing.comSarepta Therapeutics Shares Down 3% on FDA's Clinical Hold on SRP-5051June 23, 2022 | seekingalpha.comSarepta sheds 12% as FDA imposes clinical hold on Duchenne candidateJune 23, 2022 | finance.yahoo.comSarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular DystrophyJune 23, 2022 | finance.yahoo.comSarepta stock plunges after FDA puts study on holdJune 17, 2022 | nasdaq.comNotable Friday Option Activity: SAVA, SRPT, MAJune 17, 2022 | nasdaq.comFirst Week of SRPT February 2023 Options TradingJune 15, 2022 | marketwatch.comSarepta Therapeutics Inc. Com SRPT Technical Pivots with Risk ControlsJune 4, 2022 | marketwatch.comSarepta Therapeutics Inc. Com SRPT Proactive StrategiesSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(857) 242-4000Fax425-354-5038Employees840Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today6/26/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$119.25 High Stock Price Forecast$155.00 Low Stock Price Forecast$74.00 Forecasted Upside/Downside+58.5%Consensus RatingModerate Buy Rating Score (0-4)2.76923076923077 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($4.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-418.78 million Net Margins-46.56% Pretax Margin-46.45% Return on Equity-52.06% Return on Assets-12.27% Debt Debt-to-Equity Ratio1.28 Current Ratio5.56 Quick Ratio5.13 Sales & Book Value Annual Sales$701.89 million Price / Sales9.38 Cash FlowN/A Price / Cash FlowN/A Book Value$10.66 per share Price / Book7.06Miscellaneous Outstanding Shares87,500,000Free Float82,338,000Market Cap$6.58 billion OptionableOptionable Beta1.29 Sarepta Therapeutics Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Sarepta Therapeutics stock. View analyst ratings for Sarepta Therapeutics or view top-rated stocks. What is Sarepta Therapeutics' stock price forecast for 2022? 13 Wall Street analysts have issued 12 month price targets for Sarepta Therapeutics' shares. Their SRPT stock forecasts range from $74.00 to $155.00. On average, they anticipate Sarepta Therapeutics' stock price to reach $119.25 in the next year. This suggests a possible upside of 58.5% from the stock's current price. View analysts' price targets for Sarepta Therapeutics or view top-rated stocks among Wall Street analysts. How has Sarepta Therapeutics' stock performed in 2022? Sarepta Therapeutics' stock was trading at $90.05 at the beginning of 2022. Since then, SRPT shares have decreased by 16.5% and is now trading at $75.22. View the best growth stocks for 2022 here. When is Sarepta Therapeutics' next earnings date? Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Sarepta Therapeutics. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings results on Wednesday, May, 4th. The biotechnology company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.35) by $0.15. The biotechnology company had revenue of $210.83 million for the quarter, compared to analyst estimates of $208.25 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 52.06% and a negative net margin of 46.56%. Sarepta Therapeutics's quarterly revenue was up 43.5% on a year-over-year basis. During the same period in the prior year, the business earned ($2.10) EPS. View Sarepta Therapeutics' earnings history. What guidance has Sarepta Therapeutics issued on next quarter's earnings? Sarepta Therapeutics issued an update on its FY 2022 earnings guidance on Tuesday, March, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $880 M-, compared to the consensus revenue estimate of $908.46 million. Who are Sarepta Therapeutics' key executives? Sarepta Therapeutics' management team includes the following people: Mr. Douglas S. Ingram Esq., Pres, CEO & Director (Age 59, Pay $1.55M) (LinkedIn Profile)Mr. Ian Michael Estepan, Exec. VP & CFO (Age 46, Pay $861.75k)Mr. William F. Ciambrone, Exec. VP of Technical Operations (Age 58, Pay $780.28k)Dr. Louise R. Rodino-Klapac Ph.D., Exec. VP, Chief Scientific Officer and Head of R&D (Age 44, Pay $929.68k) (LinkedIn Profile)Mr. Ryan E. Brown, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44, Pay $913.64k)Mary Jenkins, Sr. Mang. of Investor RelationsMs. Alison Nasisi, Chief People Officer & VPDr. Diane L. Berry, Sr. VP of Global Health Policy and Gov. & Patient AffairsMr. Dallan Murray, Sr. VP & Chief Customer OfficerMr. Joseph Bratica, Controller & VP (Age 58) (LinkedIn Profile) What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Sarepta Therapeutics' key competitors? Some companies that are related to Sarepta Therapeutics include Royalty Pharma (RPRX), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF), Catalent (CTLT), Horizon Therapeutics Public (HZNP), BeiGene (BGNE), Alnylam Pharmaceuticals (ALNY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Viatris (VTRS), Ono Pharmaceutical (OPHLF) and United Therapeutics (UTHR). View all of SRPT's competitors. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). What is Sarepta Therapeutics' stock symbol? Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT." Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.50%), Sands Capital Management LLC (5.47%), Wellington Management Group LLP (3.06%), Bellevue Group AG (1.32%), Farallon Capital Management LLC (1.13%) and Goldman Sachs Group Inc. (1.06%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme. View institutional ownership trends for Sarepta Therapeutics. Which institutional investors are selling Sarepta Therapeutics stock? SRPT stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Victory Capital Management Inc., Zurcher Kantonalbank Zurich Cantonalbank , Goldman Sachs Group Inc., Tekla Capital Management LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., and Simplex Trading LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last two years include Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, and Richard Barry. View insider buying and selling activity for Sarepta Therapeutics or view top insider-selling stocks. Which institutional investors are buying Sarepta Therapeutics stock? SRPT stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Wellington Management Group LLP, Bank of Montreal Can, Prudential Financial Inc., Assenagon Asset Management S.A., Bellevue Group AG, Allspring Global Investments Holdings LLC, and Farallon Capital Management LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, and Louise Rodino-Klapac. View insider buying and selling activity for Sarepta Therapeutics or or view top insider-buying stocks. How do I buy shares of Sarepta Therapeutics? Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sarepta Therapeutics' stock price today? One share of SRPT stock can currently be purchased for approximately $75.22. How much money does Sarepta Therapeutics make? Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $6.58 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418.78 million in net income (profit) each year or ($4.24) on an earnings per share basis. How many employees does Sarepta Therapeutics have? Sarepta Therapeutics employs 840 workers across the globe. How can I contact Sarepta Therapeutics? Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (857) 242-4000, via email at [email protected], or via fax at 425-354-5038. This page (NASDAQ:SRPT) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here